Optimizing HBV Prevention When Switching to Long-Acting Cabotegravir/Rilpivirine. Foncillas A, Ambrosioni J, de la Mora L, Mallolas J, et al. Clin Infect Dis 2026 Apr 3:ciag218. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Foncillas A, Ambrosioni J, de la Mora L, Mallolas J, et al. Optimizing HBV Prevention When Switching to Long-Acting Cabotegravir/Rilpivirine. Clin Infect Dis 2026 Apr 3:ciag218. doi: 10.1093.
PMID: 41927056